Dr. Mittendorff leads Healthcare at B Capital ($6B AUM) and focuses, with his team, on investing capital in venture and growth opportunities in the sector. He has been involved in investments and associated exits with public equity value or acquisition value that exceed a total of $10B. He is focused on companies in digital health, health tech, biotech, and innovative medtech. Previously, he was at Norwest as Partner and Co-Head of Healthcare. He is a board certified emergency physician and former public company operating executive with experience that spans investing, complex business development transactions, the leadership of clinical advisory boards, product development, clinical trials, commercial activities, and clinical services management. He is a Fellow of the American Academy of Emergency Medicine (FAAEM).He currently serves on the board of Atomwise, Hotspot Therapeutics, Carlsmed, CapitalRX, Lively (HSA), Aetion (obs), Nalu (obs), Carrick, Volastra (obs), and Triumvira. He previously served on the boards of Impel Neuropharma, Avalyn Pharma, VisitPay, TigerConnect, Neocis, and was a board observer at Talkspace, Omada, and Route92 (investments led at Norwest). He was a board member at Silk Road Medical (SILK), iCardiac (acq. by eResearch), and Telcare (acq. by BioTelemetry), and was a previous board observer at Intersect ENT (Nasdaq: XENT), and iRhythm Technologies (Nasdaq: IRTC). Dr. Mittendorff was involved with the initial NVP investments in Misfit Wearables (acq. by Fossil) and Health Catalyst (HCAT). He also led seed investments in Myome, Excision Biosciences, and Clerio.Prior to his career in venture capital, Dr. Mittendorff was an executive officer and the Vice President of Marketing and Business Development at Hansen Medical Inc. (Nasdaq: HNSN, acquired by Auris, Auris acquired by JNJ for $3.5B in ‘19). He launched multiple products including the Magellan & Sensei X robots and led the Company’s partnerships with GE, Siemens, Philips and St. Jude Medical In transactions above $100M. He created the SAB and pitched in a $30M public financing.Dr. Mittendorff has also worked in portfolio strategy at Merck and as a management consultant at BCG. He earned a Harvard M.D., trained at Stanford in Emergency Medicine, and received his M.B.A. from Harvard and his B.S. in biomedical engineering from Johns Hopkins (high hon) where he was a varsity athlete. He also holds an MA in International Affairs from King’s College London, where he pursued research on the political economy of innovation and its effect on political realism.